[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangdong Second Provincial General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":122},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,70,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644460","phase-1-luspatercept-for-cia-in-aml-100644460",false,"NCT07663864","Luspatercept for CIA in AML","Efficacy and Safety of Luspatercept in Treating Chemotherapy-inducing Anemia in Acute Myeloid Leukemia: a Multicenter, Prospective, Single-arm Study","Inclusion Criteria:\n\n1. De novo AML patients;\n2. Age ≥ 18 years and ≤ 60 years;\n3. AML with ELN2022-low risk\n4. Received 1-3 cycles of HDAC consolidation therapy\n5. HGB 60-90 G\u002FL\n6. Eastern Cooperative Oncology Group (ECOG) score ≤ 2 points;\n7. Life expectancy ≥ 3 months;\n8. Signed informed consent and able to understand and comply with the procedures required by this protocol.\n\nExclusion Criteria:\n\n1. t-AML\u002FsAML\n2. Concurrent myelofibrosis\n3. Patients unresponsive to red blood cell transfusions\n4. Heart function \\\u003C grade 2\n5. Renal function: creatinine clearance \\\u003C 30 ml\u002Fmin\n6. Liver function: ALTd \\> 5 times normal, bilirubin \\> 3 times normal\n7. Uncontrolled hypertension, defined as recurrent elevations in diastolic blood pressure (DBP) ≥ 100 mmHg despite adequate treatment\n8. History of stroke, deep vein thrombosis (DVT), pulmonary or arterial embolism within 6 months prior to randomization\n9. Uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent infection-related signs\u002Fsymptoms that do not improve despite appropriate antibiotic, antiviral, and\u002For other treatments), known human immunodeficiency virus (HIV), active hepatitis B virus (HBV) infection, and\u002For hepatitis C. (HCV) infection\n10. History of severe allergy or allergic reaction to recombinant proteins, or allergy to rotezip or excipients\n11. Pregnant or breastfeeding women\n12. Patients deemed unsuitable for enrollment by the investigators","ALL","18 Years","60 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.",[28],"Chemotherapy-inducing Anemia",[30,31,32,33],"Acute myeloid leukemia","Chemotherapy","Anemia","Luspatercept","RECRUITING","2026-06-17",{"date":37,"type":38},"2026-06-23","ACTUAL",{"date":40,"type":21},"2026-06-01",{"date":42,"type":21},"2027-05-31",{"name":44,"class":45},"Guangdong Second Provincial General Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100580227","mobile-phone-thermal-imaging-assessment-of-incompetent-perforator-veins-100580227","NCT06834555","Mobile Phone Thermal Imaging Assessment of Incompetent Perforator Veins","Can Mobile Phone Thermal Imaging Provide an Ambulatory Assessment of Incompetent Perforator Veins?","Inclusion Criteria:\n\nA diagnosis of CVD by vascular surgeon, classified C0 to C6 according to CEAP (Clinical-Etiology - Anatomy - Pathophysiology) No history of lower extremity surgery The body mass index (BMI) is 18 to 35 kg\u002Fm2\n\nExclusion Criteria:\n\ndeep vein thrombosis heart disease peripheral artery disease chronic liver disease chronic kidney disease pregnancy severe obesity (BMI ≥35 kg\u002Fm2)",{"count":55,"type":21},100,[57],"NA","Chronic venous disease is a common disease of the lower limbs. Severe CVD can lead to lower limb swelling, pigmentation, and repeated skin ulceration, which seriously affects patients' quality of life. About 10.5% to 92.7% of CVD patients with recurrent varicose veins had insufficient perforating veins. Treatment of these IPVs can promote venous ulcer healing and reduce the recurrence rate of venous ulcers. Accurate assessment and positioning of insufficient perforating veins in the lower leg is a key step in developing a personalized treatment strategy. At present, Color Doppler ultrasonography performed in the upright position in combination with the Valsalva maneuver or local pressure of the limb is regarded as the \"gold standard\" for the diagnosis of perforating veins insufficiency. However, in China, a large number of perforating veins insufficiency are diagnosed by venography. Because the majority of Chinese vascular surgeons are not versatile in vascular ultrasound examination and venous ultrasound protocols vary from institution to institution. A non-functioning valve in an insufficient perforated vein allows blood to flow retrograde from a deep vein to a superficial vein. Some researchers have shown that the venous blood temperature of deep veins is higher than that of superficial veins. Thus, the retrograde flow of \"warm blood\" from the deep vein to the superficial vein increases the skin temperature located on the insufficient perforated vein. This study tested the feasibility of a smartphone and its compatible portable thermal imaging device as a tool for assessing insufficient perforated vein. The objective is to study the sensitivity and specificity of smartphone thermal imaging in diagnosing and locating the insufficient perforated vein in CVD patients.",[60],"Chronic Venous Disease","NOT_YET_RECRUITING","2025-02-13",{"date":64,"type":38},"2025-02-19",{"date":66,"type":21},"2025-03-01",{"date":68,"type":21},"2025-12-01",{"name":44,"class":45},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":46},"100574386","to-assess-the-effectiveness-and-safety-of-catheter-based-focal-intracranial-hypothermia-combined-with-endovascular-reperfusion-therapy-for-patients-with-acute-anterior-circulation-large-artery-occlusion-100574386","NCT06758609","To Assess the Effectiveness and Safety of Catheter-based Focal Intracranial Hypothermia Combined with Endovascular Reperfusion Therapy for Patients with Acute Anterior Circulation Large Artery Occlusion","Local Hypothermia and Endovascular Recanalization for Acute Large Artery Occlusive Stroke-A Multicenter, Prospective, Open-label, Blinded-Endpoint, Randomized Controlled Trial","CHILL-ART","Inclusion Criteria:\n\n1. Age ≥18 and ≤85 years old.\n2. Symptoms of sudden focal or general neurological impairment.\n3. There may be a causal relationship between vascular occlusion and nerve function defect.\n4. Time from symptom onset to randomization ≤24h.\n5. The National Institutes of Health Stroke Scale (NIHSS) score was ≥6 points before randomization.\n6. According to the judgment of the clinician, the operation path is reasonable, and the operation and operation related instruments can reach the disease smoothly.\n7. Patients or their guardians can understand the purpose of the trial, voluntarily participate and sign a written informed consent, and are capable of receiving clinical follow-up.\n8. Prior to randomization, CTA, MRA, or DSA confirmed the presence of anterior circulatory large vessel occlusion (internal carotid artery or M1segment).\n9. The symptoms are aggravated by recurrent cerebral infarction in the same drainage basin and\u002For the pathogenesis is caused by decreased blood perfusion.\n\nExclusion Criteria:\n\n1. Pre stroke mRS\\>1 score.\n2. There are acute infarcts in both cerebral hemispheres and\u002For anterior and posterior circulation.\n3. NIHSS≤6 points.\n4. Cerebral hemorrhage\u002Fsubarachnoid hemorrhage was confirmed by CT or MRI. 5.The presence of active bleeding, severe anemia, coagulation dysfunction, or an uncorrected bleeding tendency (Presence of at least one of the following laboratory tests: hemoglobin \\\u003C 10g \u002Fdl, platelet count \\\u003C 100,000 \u002Fμl, uncorrected INR\\>1.5, PT\\> 1 minute above the upper limit of normal, or heparin-related thrombocytopenia).\n\n6.Patients with heart function of grade 1 or above, or with a clear history of acute or chronic heart dysfunction, are at greater risk of acute heart failure or fluid perfusion intolerance as determined by clinicians.\n\n7\\. Severe heart, liver, kidney disease. 8.With malignant diseases such as malignant tumors, the expected survival time is less than 3 months.\n\n9.Participating in other clinical trials, in the investigational phase or in the follow-up phase.","85 Years",{"count":80,"type":21},262,[57],"A multicenter, prospective, open-label, blinded-endpoint, randomized controlled trial to assess the effectiveness and safety of catheter-based focal intracranial hypothermia combined with endovascular reperfusion therapy for patients with acute anterior circulation large artery occlusion.",[84,85,86,87],"Acute Cerebrovascular Accident","Acute Ischemic Stroke","Internal Carotid Artery","Middle Cerebral Artery Occlusion","2024-12-27",{"date":90,"type":38},"2025-01-06",{"date":92,"type":38},"2024-12-01",{"date":94,"type":21},"2026-06-30",{"name":44,"class":45},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":111,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":46},"100539009","early-phase-1-to-assess-safety-tolerability-and-efficacy-of-anti-gprc5d-cd19-car-t-in-relapsedrefractory-multiple-myeloma-100539009","NCT06298266","To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed\u002FRefractory Multiple Myeloma","Clinical Study to Evaluate the Safety, Tolerability and Initial Efficacy of Anti-GPRC5D-CD19-CAR-T in Patients With Relapsed\u002FRefractory Multiple Myeloma","Inclusion Criteria:\n\n* 1\\. The patient or their legal guardian understands and voluntarily signs the informed consent form and is expected to complete the follow-up examinations and treatments.\n\n  2\\. Age between 18-75 years, regardless of gender. 3. Diagnosed with multiple myeloma according to the IMWG diagnostic criteria, and GPRC5D expression in bone marrow is positive (\\>10%).\n\n  4\\. Has failed treatment with at least three different mechanisms of drugs (including chemotherapy, proteasome inhibitors, immune modulators, etc.), or has experienced disease progression or relapse within 6 months after the last treatment.\n\n  5\\. Measurable lesions are present based on any of the following criteria during screening: (1) Serum monoclonal immunoglobulin (M-protein) level ≥1.0 g\u002FdL; (2) Urine M-protein level ≥200 mg\u002F24 hours; (3) Diagnosed with light chain multiple myeloma with no measurable lesions in serum or urine: Serum free light chain ≥10 mg\u002FdL and abnormal serum free light chain κ\u002Fγ ratio.\n\n  6\\. The patient has recovered from toxicities associated with previous treatment, i.e., CTCAE toxicity grade \\\u003C2 (unless the abnormality is related to the tumor or stable, with no significant impact on safety or efficacy as determined by the investigator).\n\n  7\\. ECOG performance status of 0-2 and an expected survival of more than 3 months.\n\n  8\\. Adequate organ function:\n* Alanine transaminase (ALT) ≤3 times the upper limit of normal (ULN);\n* Aspartate transaminase (AST) ≤3 times ULN;\n* Total bilirubin ≤1.5 times ULN;\n* Serum creatinine ≤1.5 times ULN, or creatinine clearance ≥60 mL\u002Fmin;\n* Indoor oxygen saturation ≥92%;\n* Left ventricular ejection fraction (LVEF) ≥45%, confirmed by echocardiography with no clinically significant pericardial effusion or clinically significant electrocardiogram findings;\n* No clinically significant pleural effusion. 9. Able to establish the required venous access for sample collection, with no contraindications for white blood cell collection.\n\nExclusion Criteria:\n\n* 1\\. Diagnosed with or treated for invasive malignant tumors other than multiple myeloma.\n\n  2\\. Previously received anti-tumor treatments including targeted therapy, epigenetic therapy, experimental drug therapy, or invasive experimental medical devices within 14 days or at least 5 half-lives (whichever is shorter) before the collection and preparation of CAR-T cells. Also, received monoclonal antibody therapy for relapsed\u002Frefractory multiple myeloma within 21 days, received cytotoxic therapy within 14 days, received proteasome inhibitor therapy within 14 days, received immunomodulatory agent therapy within 7 days, or received radiation therapy within 14 days (except for bone marrow reserves with field coverage ≤5%).\n\n  3\\. Suspected involvement of multiple myeloma in the central nervous system or meninges confirmed by MRI or CT, or presence of other active central nervous system diseases.\n\n  4\\. Screening criteria include plasma cell leukemia (according to standard classification, plasma cells \\>2.0×109\u002FL), Waldenstrom macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or secondary AL amyloidosis.\n\n  5\\. Positive for hepatitis B surface antigen (HBsAg) and positive for HBV-DNA; positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; cytomegalovirus (CMV) DNA test result ≥500 copies\u002FmL; positive for syphilis test.\n\n  6\\. Positive for hepatitis C virus (HCV) antibody; positive for human immunodeficiency virus (HIV) antibody; cytomegalovirus (CMV) DNA test result ≥500 copies\u002FmL; positive for syphilis test.\n\n  7\\. History of severe allergies defined as grade II or above reactions, with clinical manifestations including airway obstruction (runny nose, coughing, wheezing, difficulty breathing), tachycardia, hypotension, arrhythmia, gastrointestinal symptoms (nausea, vomiting), urinary or fecal incontinence, laryngeal edema, bronchospasm, cyanosis, shock, respiratory or cardiac arrest, or known allergy to any active ingredient, excipient, murine-derived product, or xenogeneic protein contained in this trial (including the CleenRx regimen).\n\n  8\\. Severe cardiac diseases including but not limited to severe arrhythmias, unstable angina pectoris, extensive myocardial infarction, New York Heart Association Class III or IV heart failure, myocardial infarction within 6 months before screening or coronary artery bypass graft (CABG), unexplained history of syncope unrelated to vasovagal or dehydration, severe non-ischemic cardiomyopathy, or uncontrolled hypertension (defined as failure to achieve blood pressure goals despite using ≥3 antihypertensive drugs, including diuretics, for ≥1 month or effective blood pressure control requiring ≥4 antihypertensive drugs).\n\n  9\\. Unstable systemic diseases, including but not limited to severe liver, kidney, or metabolic diseases requiring medication.\n\n  10\\. Acute\u002Fchronic graft-versus-host disease (GVHD) within 6 months before screening or patients requiring immunosuppressive therapy for GVHD.\n\n  11\\. Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barré syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically significant active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES)).\n\n  12\\. Presence of tumor emergencies (e.g., spinal cord compression, intestinal obstruction, leukostasis, tumor lysis syndrome) requiring urgent treatment during screening or before cell infusion.\n\n  13\\. Uncontrolled bacterial, fungal, viral, or other infections requiring antibiotic treatment.\n\n  14\\. Underwent major surgery (excluding diagnostic surgery and biopsies) within 4 weeks before CleenRx or planned major surgery during the study, or incomplete healing of surgical wounds before enrollment.\n\n  15\\. Received (attenuated) live virus vaccines within 4 weeks before screening. 16. Presence of severe mental disorders. 17. Alcohol or substance abuse history. 18. Pregnant or breastfeeding women, and female subjects or male subjects with partners planning pregnancy within 2 years after cell infusion, and subjects who plan to become pregnant within 2 years after cell infusion. Additionally, according to the investigator's judgment and\u002For clinical criteria, patients with contraindications to any study procedures or other medical conditions that may expose them to unacceptable risks.","75 Years",{"count":105,"type":21},15,[107],"EARLY_PHASE1","To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma",[110],"Relapsed or Refractory Multiple Myeloma",[112,113],"GPRC5D-CD19 CART","Multiple myeloma","2024-03-05",{"date":116,"type":38},"2024-03-07",{"date":118,"type":21},"2024-03-29",{"date":120,"type":21},"2026-12-31",{"name":44,"class":45},""]